RingConn eliminates blood pressure beta as the next section will focus on
RingConn is closing its Blood Pressure Insights Beta at the end of March, with users already receiving confirmation within the app. The move comes six months after the feature first appeared and raises questions about what happens next.
There are several ways to read this, and none of them point to a feature that simply disappears.
Beta is ending but not a feature
The message sent to users is straightforward. The beta ends on March 31st and the feature will no longer be available in its current form. That sounds sudden, but it’s actually common in health features that rely on calibration and algorithm tuning.
Blood pressure measurement on wearables is not a direct sensor reading. It relies on indirect signals, usually pulse transit time or similar metrics, combined with measurement data. That means beta sessions are often used to collect large data sets and refine models before a wider release.
From that point of view, ending the beta can only mean one thing. Data collection phase is done.
The timelines are consistent with the wider release
The October 2025 beta start date gives you a reasonable window to gather enough variation across users, situations and daily routines. Closing it at the end of March creates a clean break before whatever comes next. That would be a reworked version of the feature, possibly with stricter rating requirements or improved compatibility.
It’s also worth noting that companies rarely keep a beta running indefinitely if they plan to ship a feature widely. At some point, they need to lock the model and go to the production version.
Where does this leave the Gen 2 devices
But who really gets the feature. This is where things get unclear. If blood pressure was already working on existing hardware during beta, that suggests that Gen 2 devices are technically capable of supporting it.
The question is whether RingConn wants to keep it there.
There are two competing incentives. On the other hand, rolling it out to existing users builds trust and adds value to devices already in the wild. On the other hand, blood pressure is a headline feature that can help sell new hardware.
A middle ground is possible. The company can bring a basic version to Gen 2 while keeping a more refined or easy-to-use implementation for new devices.
Gen 3 already points to the answer
The strongest clue comes from the upcoming Gen 3 ring. That device is already positioned to track blood pressure as one of its key capabilities.
That makes it impossible for the feature to be discarded. It is likely to be held for a more controlled launch.
There is also a working angle. If Gen 3 includes changes in sensor architecture or signal processing, algorithms developed during beta may perform better on that hardware. If so, RingConn may choose to synchronize the full release with the new device.
A more likely scenario is reintroduction than disappearance. The beta ends, the feature goes away for a while, and then comes back in a more refined form.
That could happen as a software update for existing users, or it could arrive around Gen 3 as a patchy capability and drop over time. Either way, it probably won’t be long before we find out. But it seems to us that RingConn has gathered what it needs and is now preparing for the next step.
Sign up for our monthly newsletter! Check out our YouTube channel.
And of course, you can follow Gadgets & Wearables on Google News and add us as a favorite source to get our expert news, reviews, and opinions in your feed.
The post RingConn ends blood pressure beta as the next phase will focus first on Gadgets and Wearables.
